pharma · Metachromatic Leukodystrophy (MLD) · Late Metachromatic Leukodystrophy (MLD)
Shire
Shire is a pharma organization headquartered in CN. Primary therapeutic focus areas include Metachromatic Leukodystrophy (MLD), Late Metachromatic Leukodystrophy (MLD), Hunter Syndrome, Cytomegalovirus (CMV), Crohn's Dis
JP HQ
3,523 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- JP
- Employees
- 3,523
- Programs
- 9
- Drugs
- 8
- Patents
- 0
Elaprase for intravenous (IV) infusion
Approved · small molecule · Hunter Syndrome
Elaprase for intravenous (IV) infusion for Hunter Syndrome is a Approved program (small_molecule) at Shire with 1 ClinicalTrials.gov record(s).
Internal code SHP-ELA-401
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shire
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Hunter Syndrome
- Status
- completed
- Trials
- 1